Compare WHR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHR | LQDA |
|---|---|---|
| Founded | 1911 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.4B |
| IPO Year | 1994 | 2020 |
| Metric | WHR | LQDA |
|---|---|---|
| Price | $44.76 | $42.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $74.33 | $41.00 |
| AVG Volume (30 Days) | ★ 2.4M | 930.9K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | ★ 196.42 | 51.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,253,000,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $278.87 |
| Revenue Next Year | $3.48 | $57.13 |
| P/E Ratio | $8.44 | ★ N/A |
| Revenue Growth | 2.58 | ★ 1031.18 |
| 52 Week Low | $44.87 | $11.85 |
| 52 Week High | $111.96 | $46.67 |
| Indicator | WHR | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 28.44 | 65.57 |
| Support Level | N/A | $35.00 |
| Resistance Level | $58.16 | $46.67 |
| Average True Range (ATR) | 2.51 | 1.65 |
| MACD | -0.68 | 0.46 |
| Stochastic Oscillator | 0.71 | 92.74 |
Whirlpool Corp is a manufacturer and marketer of kitchen and laundry appliances, with its presence in different markets around the world. It offers products like refrigerators, washing machines, cooktops, ovens, freezers, and others, which are marketed through various brands such as KitchenAid, Maytag, Amana, Brastemp, Consul, Whirlpool, Jennair, etc. The company's operating and reportable segments are: Major Domestic Appliances (MDA) North America (its key revenue-generating segment), MDA Europe, MDA Latin America, and Small Domestic Appliances (SDA) Global.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.